[1] Hulvat MC. Cancer incidence and trends. Surg Clin. 2020;100:469-81. [2] Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 2018;9:1300. [3] Cruz-Reyes N, Radisky DC. Inflammation, infiltration, and evasion—tumor promotion in the aging breast. Cancers. 2023;15:1836. [4] WHO. Cancer. 2022. [5] Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49. [6] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48. [7] Tenore G, et al. Tobacco, alcohol and family history of cancer as risk factors of oral squamous cell carcinoma: case-control retrospective study. Appl Sci. 2020;10:3896. [8] An S-Y, et al. Obesity is positively related and tobacco smoking and alcohol consumption are negatively related to an increased risk of thyroid cancer. Sci Rep. 2020;10:19279. [9] Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Drug Resist Combat Drug Resist Cancer. 2019;2:141-60. [10] Yosri N, et al. Marine organisms: pioneer natural sources of polysaccharides/proteins for green synthesis of nanoparticles and their potential applications. Int J Biol Macromol. 2021;193:1767-98. [11] El-Seedi HR, et al. Exploring natural products-based cancer therapeutics derived from Egyptian flora. J Ethnopharmacol. 2021;269:113626. [12] Carroll AR, Copp BR, Davis RA, Keyzers RA, Prinsep MR. Marine natural products. Nat Prod Rep. 2021;38:362-413. [13] Carroll AR, Copp BR, Davis RA, Keyzers RA, Prinsep MR. Marine natural products. Nat Prod Rep. 2023;40:275-325. [14] Lu W-Y, Li H-J, Li Q-Y, Wu Y-C. Application of marine natural products in drug research. Bioorg Med Chem. 2021;35:116058. [15] El-Seedi HR, et al. Review of marine cyanobacteria and the aspects related to their roles: chemical, biological properties, nitrogen fixation and climate change. Mar Drugs. 2023;21:439. [16] Montuori E, Hyde CAC, Crea F, Golding J, Lauritano C. Marine natural products with activities against prostate cancer: recent discoveries. Int J Mol Sci. 2023;24:1435. [17] Khalifa SAM, et al. Marine natural products: a source of novel anticancer drugs. Mar Drugs. 2019;17:491. [18] Hentschel U, Piel J, Degnan SM, Taylor MW. Genomic insights into the marine sponge microbiome. Nat Rev Microbiol. 2012;10:641-54. [19] Perdicaris S, Vlachogianni T, Valavanidis A. Bioactive natural substances from marine sponges: new developments and prospects for future pharmaceuticals. Nat Prod Chem Res. 2013;1:2329-6836. [20] Radjasa OK, et al. Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associants. Bioorg Med Chem. 2011;19:6658-74. [21] Altmann K-H. Drugs from the oceans: marine natural products as leads for drug discovery. Chimia. 2017;71:646. [22] Cappello E, Nieri P. From life in the sea to the clinic: the marine drugs approved and under clinical trial. Life. 2021;11:1390. [23] De AK, et al. A natural quinazoline derivative from marine sponge Hyrtios erectus induces apoptosis of breast cancer cells via ROS production and intrinsic or extrinsic apoptosis pathways. Mar Drugs. 2019;17:658. [24] Jomori T, Setiawan A, Sasaoka M, Arai M. Cytotoxicity of new diterpene alkaloids, ceylonamides G-I, isolated from Indonesian marine sponge of Spongia sp. Nat Prod Commun. 2019;14:1934578X19857294. [25] Sakai R, et al. Soritesidine, a novel proteinous toxin from the okinawan marine sponge Spongosorites sp. Mar Drugs. 2019;17:216. [26] Wu Y, et al. Phakefustatins A-C: kynurenine-bearing cycloheptapeptides as RXRα modulators from the marine sponge Phakellia fusca. Org Lett. 2020;22:6703-8. [27] Ki D-W, et al. New cytotoxic polyacetylene amides from the Egyptian marine sponge Siphonochalina siphonella. Fitoterapia. 2020;142:104511. [28] Surti M, et al. Ilimaquinone (marine sponge metabolite) induces apoptosis in HCT-116 human colorectal carcinoma cells via mitochondrial-mediated apoptosis pathway. Mar Drugs. 2022;20:582. [29] Wang Z, et al. Kalihioxepanes A—G: seven kalihinene diterpenoids from marine sponge Acanthella cavernosa collected off the south China Sea. Chin J Chem. 2022;40:1785-92. [30] Carpi S, et al. Pro-apoptotic activity of the marine sponge Dactylospongia elegans metabolites pelorol and 5-epi-ilimaquinone on human 501Mel melanoma cells. Mar Drugs. 2022;20:427. [31] Zhou M, et al. 12-deacetyl-12-epi-scalaradial, a scalarane sesterterpenoid from a marine sponge Hippospongia sp., induces HeLa cells apoptosis via MAPK/ERK Pathway and modulates nuclear receptor Nur77. Mar Drugs. 2020;18:643. [32] Ki D-W, et al. New cytotoxic polyacetylene alcohols from the Egyptian marine sponge Siphonochalina siphonella. J Nat Med. 2020;74:409-14. [33] Yu H-B, et al. Cytotoxic meroterpenoids from the marine sponge Dactylospongia elegans. Nat Prod Res. 2021;35:1620-6. [34] Tran HN, Kim MJ, Lee Y-J. Scalarane sesterterpenoids isolated from the marine sponge Hyrtios erectus and their cytotoxicity. Mar Drugs. 2022;20:604. [35] Chikamatsu S, et al. In vitro and in vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells. Cancer Med. 2019;8:5662-72. [36] Cheng S-Y, et al. Anti-invasion and antiangiogenic effects of stellettin B through inhibition of the Akt/Girdin signaling pathway and VEGF in glioblastoma cells. Cancers. 2019;11:220. [37] Feng C-W, et al. In vitro and in vivo neuroprotective effects of stellettin B through anti-apoptosis and the Nrf2/HO-1 pathway. Mar Drugs. 2019;17:315. [38] Ahn J-H, Woo J-H, Rho J-R, Choi J-H. Anticancer activity of Gukulenin A isolated from the marine sponge Phorbas gukhulensis in vitro and in vivo. Mar Drugs. 2019;17:126. [39] Stanojkovic TP, et al. Evaluation of in vitro cytotoxic potential of avarol towards human cancer cell lines and in vivo antitumor activity in solid tumor models. Molecules. 2022;27:9048. [40] Mohamadkhani A. Gene cluster analysis of marine bacteria seeking for natural anticancer products. Jundishapur J Nat Pharm Prod. 2021;16: e104665. [41] Kačar D, et al. Identification of trans-AT polyketide clusters in two marine bacteria reveals cryptic similarities between distinct symbiosis factors. Environ Microbiol. 2021;23:2509-21. [42] Kristoffersen V, et al. Two novel lyso-ornithine lipids isolated from an arctic marine Lacinutrix sp. bacterium. Molecules. 2021;26:5295. [43] Malhão F, et al. Cytotoxic and antiproliferative effects of preussin, a hydroxypyrrolidine derivative from the marine sponge-associated fungus Aspergillus candidus KUFA 0062, in a panel of breast cancer cell lines and using 2D and 3D cultures. Mar Drugs. 2019;17:448. [44] Farha AK, Hatha AM. Bioprospecting potential and secondary metabolite profile of a novel sediment-derived fungus Penicillium sp. ArCSPf from continental slope of Eastern Arabian Sea. Mycology. 2019;10:109-17. [45] Liu L, et al. Penicindopene A, a new indole diterpene from the deep-sea fungus Penicillium sp. YPCMAC1. Nat Prod Res. 2019;33:2988-94. [46] Cheng Z, et al. Three new cyclopiane-type diterpenes from a deep-sea derived fungus Penicillium sp. YPGA11 and their effects against human esophageal carcinoma cells. Bioorg Chem. 2019;91:103129. [47] Fan B, et al. Pyrenosetin D, a new pentacyclic decalinoyltetramic acid derivative from the algicolous fungus Pyrenochaetopsis sp. FVE-087. Mar Drugs. 2020;18:281. [48] Chen J-J, et al. Highly oxygenated constituents from a marine alga-derived fungus Aspergillus giganteus NTU967. Mar Drugs. 2020;18:303. [49] Dezaire A, et al. Secondary metabolites from the culture of the marine-derived fungus Paradendryphiella salina PC 362H and evaluation of the anticancer activity of its metabolite hyalodendrin. Mar Drugs. 2020;18:191. [50] Parthasarathy R, et al. Molecular profiling of marine endophytic fungi from green algae: assessment of antibacterial and anticancer activities. Process Biochem. 2020;96:11-20. [51] Ma M, Ge H, Yi W, Wu B, Zhang Z. Bioactive drimane sesquiterpenoids and isocoumarins from the marine-derived fungus Penicillium minioluteum ZZ1657. Tetrahedron Lett. 2020;61:151504. [52] Bae SY, et al. Antitumor activity of asperphenin A, a lipopeptidyl benzophenone from marine-derived Aspergillus sp. fungus, by inhibiting tubulin polymerization in colon cancer cells. Mar Drugs. 2020;18:110. [53] Wang F, et al. Waikikiamides A-C: complex diketopiperazine dimer and diketopiperazine-polyketide hybrids from a hawaiian marine fungal strain Aspergillus sp. FM242. Org Lett. 2020;22:4408-12. [54] Tang R, Zhou D, Kimishima A, Setiawan A, Arai M. Selective cytotoxicity of marine-derived fungal metabolite (3S,6S)-3,6-dibenzylpiperazine-2,5-dione against cancer cells adapted to nutrient starvation. J Antibiot. 2020;73:873-5. [55] Jiang L-L, et al. Cytotoxic secondary metabolites isolated from the marine alga-associated fungus Penicillium chrysogenum LD-201810. Mar Drugs. 2020;18:276. [56] Zhang J, et al. Cytotoxic secondary metabolites from a sea-derived fungal strain of Hypoxylon rubiginosum FS521. Chin J Org Chem. 2020;40:1367. [57] Feng J, et al. FGFC1 exhibits anti-cancer activity via inhibiting NF-κB signaling pathway in EGFR-mutant NSCLC cells. Mar Drugs. 2022;20:76. [58] Chen L, et al. Isolation of 4,4'-bond secalonic acid D from the marine-derived fungus Penicillium oxalicum with inhibitory property against hepatocellular carcinoma. J Antibiot. 2019;72:34-44. [59] Jayawardena TU, et al. Antiproliferative and apoptosis-inducing potential of 3$β$-hydroxy-$Δ$5-steroidal congeners purified from the soft coral Dendronephthya putteri. J Oceanol Limnol. 2019;37:1382-92. [60] Tseng WR, et al. Bioactive capnosanes and cembranes from the soft coral Klyxum flaccidum. Mar Drugs. 2019;17:9-11. [61] Hegazy MEF, et al. Sarcoehrenbergilides D-F: cytotoxic cembrene diterpenoids from the soft coral: Sarcophyton ehrenbergi. RSC Adv. 2019;9:27183-9. [62] Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. [63] Alarif WM, et al. Two new xeniolide diterpenes from the soft coral Xenia umbellata; displayed anti proliferative effects. Pharmacogn Mag. 2020;16:774-9. [64] Yang F, et al. Uncommon nornardosinane, seconeolemnane and related sesquiterpenoids from Xisha soft coral Litophyton nigrum. Bioorg Chem. 2020;96:103636. [65] Huang TY, et al. New hydroquinone monoterpenoid and cembranoid-related metabolites from the soft coral Sarcophyton tenuispiculatum. Mar Drugs. 2021;19:8. [66] Lin YC, et al. Targeted isolation of xenicane diterpenoids from Taiwanese soft coral Asterospicularia laurae. Mar Drugs. 2021;19:123. [67] Mohamed TA, et al. A new cembranoid from the Red Sea soft coral Sarcophyton acutum. Nat Prod Res. 2024;38:512. [68] Welsch JT, et al. Tuaimenals B-H, merosesquiterpenes from the Irish deep-sea soft coral Duva florida with bioactivity against cervical cancer cell lines. J Nat Prod. 2023;86:182. [69] Ghandourah MA. Cytotoxic ketosteroids from the Red Sea soft coral Dendronephthya sp. Open Chem. 2023;21:4-9. [70] Zhang J, et al. Seven new lobane diterpenoids from the soft coral Lobophytum catalai. Mar Drugs. 2023;21:451. [71] Chao CH, et al. Cembranolides and related constituents from the soft coral Sarcophyton cinereum. Molecules. 2022;27:1760. [72] Nayaka S, et al. A potential bioactive secondary metabolites and antimicrobial efficacy of Streptomyces thermocarboxydus strain KSA-2, isolated from Kali River, Karwar. Curr Res Microbiol Infect. 2020;1:5-13. [73] Fahmy NM, Abdel-Tawab AM. Isolation and characterization of marine sponge-associated Streptomyces sp. NMF6 strain producing secondary metabolite(s) possessing antimicrobial, antioxidant, anticancer, and antiviral activities. J Genet Eng Biotechnol. 2021;19:102. [74] Nadar Rajivgandhi G, et al. Molecular identification and structural detection of anti-cancer compound from marine Streptomyces akiyoshiensis GRG 6 (KY457710) against MCF-7 breast cancer cells. J King Saud Univ Sci. 2020;32:3463-9. [75] Bhattacharya B, Mukherjee S. Cancer therapy using antibiotics. J Cancer Ther. 2015;06:849-58. [76] Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol. 2011;4:687-99. [77] Al-Ansari M, Kalaiyarasi M, Almalki MA, Vijayaraghavan P. Optimization of medium components for the production of antimicrobial and anticancer secondary metabolites from Streptomyces sp. AS11 isolated from the marine environment. J King Saud Univ Sci. 2020;32:1993-8. [78] Song Y, et al. Chlorinated bis-indole alkaloids from deep-sea derived Streptomyces sp. SCSIO 11791 with antibacterial and cytotoxic activities. J Antibiot. 2020;73:542-7. [79] Nair V, et al. Verrucosamide, a cytotoxic 1,4-thiazepane-containing thiodepsipeptide from a marine-derived actinomycete. Mar Drugs. 2020;18:549. [80] Marchbank DH, Ptycia-Lamky VC, Decken A, Haltli BA, Kerr RG. Guanahanolide A, a meroterpenoid with a sesterterpene skeleton from coral-derived Streptomyces sp. Org Lett. 2020;22:6399-403. [81] Riccio G, et al. Jellyfish as an alternative source of bioactive antiproliferative compounds. Mar Drugs. 2022;20:350. [82] Riccio G, et al. Bioactivity screening of Antarctic sponges reveals anticancer activity and potential cell death via ferroptosis by mycalols. Mar Drugs. 2021;19:459. [83] Cruz C, et al. Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:3134-43. [84] Jimenez PC, et al. Enriching cancer pharmacology with drugs of marine origin. Br J Pharmacol. 2020;177:3-27. [85] Deeks ED. Polatuzumab vedotin: first global approval. Drugs. 2019;79:1467-75. [86] Sehn LH, et al. Polatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:155-65. [87] Rosenberg JE, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:2592-600. [88] Lonial S, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207-21. |